[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100517741":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":29,"collaborators":7,"id":31,"slug":32,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":36,"acronym":7,"eligibilityCriteria":37,"healthyVolunteers":33,"sex":38,"minAge":39,"maxAge":7,"enrollmentInfo":40,"targetDuration":7,"studyType":43,"phases":7,"briefSummary":44,"conditions":45,"keywords":7,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":56},{"fullName":5,"class":6},"Boryung Pharmaceutical Co., Ltd","INDUSTRY",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Shinyoung Oh","CONTACT","+82-2-708-8000","syoh@boryung.co.kr",[15],{"facility":16,"status":17,"city":18,"state":7,"zip":7,"country":19,"countryCode":7,"cosmosGeoPoint":20,"geoPoint":25,"contacts":26},"Seoul National University Boramae Medical Center","RECRUITING","Seoul","South Korea",{"type":21,"coordinates":22},"Point",[23,24],126.9784,37.566,{"lat":24,"lon":23},[27],{"name":28,"role":11,"phone":7,"phoneExt":7,"email":7},"Ki-Hwan Kim, M.D., Ph.D.",{"type":30,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100517741","observational-study-to-evaluate-the-safety-and-efficacy-of-zepzelca-injection-100517741",false,"NCT06021483","Observational Study to Evaluate the Safety and Efficacy of Zepzelca™ Injection","Observational Study to Evaluate the Safety and Efficacy of Zepzelca™ Injection (Lurbinectedin) in Patients With Metastatic Small Cell Lung Cancer (SCLC) in Real-World Practice","Inclusion Criteria:\n\n* Patients who voluntarily provide written consent for personal information collection and utilization after receiving an explanation about the objective and methods of the study\n* Patients who have received or are scheduled to receive Zepzelca™ inj., according to domestic approval indications\n* Patients with metastatic SCLC who have failed first-line platinum-based chemotherapy\n\nExclusion Criteria:\n\n* Patients with no prior history of platinum-based anticancer chemotherapy for cancer treatment\n* Patients with a history of hypersensitivity reactions to this drug or its components\n* Pregnant, potentially pregnant, or lactating women\n* Patients currently participating in another clinical trial (drug or medical device) or planning to participate in another clinical trial during the study period (except for non-interventional clinical studies or cases where the clinical trial drug administration has ended and only follow-up is remaining)\n* Patients who are judged by the principle Investigator or sub-Investigator to be ineligible to participate in the study.","ALL","19 Years",{"count":41,"type":42},300,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to evaluate the safety and efficacy of Zepzelca™ inj. in real-world practice and to investigate important identified risks and gaps in information related to risk management plans.",[46],"SCLC","2025-09-14",{"date":49,"type":50},"2025-09-16","ACTUAL",{"date":52,"type":50},"2023-08-16",{"date":54,"type":42},"2025-09",{"name":5,"class":6},1]